RNA Therapy Clinical Trials Market (2026 - 2033)

RNA Therapy Clinical Trials Market Summary

The global RNA therapy clinical trials market size was valued at USD 4.5 billion in 2025 and is projected to grow from USD 5.0 billion in 2026 to USD 9.8 billion by 2033, at a CAGR of 10.2% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 36.0% in 2025. The market growth is majorly driven by the growing prevalence of genetic and rare diseases, a rise in R&D funding, the demand for novel therapies, and a favorable regulatory environment.

For instance, in November 2025, the DNA to RNA Initiative (D2R) awarded nearly USD 5.3 billion, with an additional USD 3.9 billion specifically for training. This investment is projected to support several research projects at McGill University, the University of British Columbia, and the Université de Sherbrooke, including initiatives involving researchers at the Rosalind and Morris Goodman Cancer Institute (GCI). The funds aim to facilitate advancements in RNA science and therapeutics.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Moreover, the increasing approval of RNA therapies is expected to drive market growth. Numerous oligonucleotide drugs are approved, and multiple are in phase III clinical trials, mainly for genetically well-defined rare disorders. The current bolus of investment in RNA therapeutics is likely to lead the future clinical success across multiple modalities and disease areas.

The success of RNA-based COVID-19 vaccines has been a major driver of the RNA therapy clinical trial industry. The development and widespread use of COVID-19 mRNA vaccines by Pfizer-BioNTech and Moderna have demonstrated the potential of RNA therapeutics worldwide. The safety and efficacy of mRNA-based technologies have been strongly demonstrated by the approval of mRNA vaccines. This approval has propelled confidence among regulatory bodies, researchers, and investors, encouraging further exploration of mRNA therapeutics in clinical trials. Furthermore, the success of mRNA vaccines has led to significant attention from funding organizations and investors. The growing interest in mRNA therapies has attracted additional funding opportunities, enabling more research institutions and entities to carry out clinical trials in the arena. For instance, in December 2025, the Coalition for Epidemic Preparedness Innovations (CEPI) announced an investment of nearly USD 54.3 billion to support the Phase 3 clinical trial, which aimed to help Moderna secure licensure for its mRNA-based H5 pandemic influenza vaccine candidate.

The increasing prevalence of genetic and rare diseases is expected to drive the development of novel RNA therapies and significant growth in this market in the coming years. According to the U.S. Department of Health & Human Services, over 10,000 known rare disorders affect around 1 in 10 individuals (about 30 billion) in the U.S. Globally, an estimated 3.5 to 5.9% of people have a rare disease, many of which are RNDs, which are usually identified in childhood. mRNA technology enables the development of a broad range of therapeutic modalities, including gene editing, protein replacement, and cancer immunotherapy. This versatility makes mRNA therapy a useful platform for addressing various rare diseases, resulting in boosting market growth.

On the other hand, the increasing adoption of mRNA in cancer vaccines is also expected to boost market growth during the forecast period. For the treatment of melanoma, colorectal, and pancreatic cancer using an mRNA vaccine, numerous clinical trials are now being conducted. mRNA cancer vaccines can be used as a personalized therapy or as a one-vaccine-to-many-people technique. Dendritic cells take the vaccine's mRNA and deliver it to T cells, directing them to search out and eliminate cancer cells.

Analyst Perspective

The global RNA therapy clinical trials industry is growing rapidly, driven by a strong pipeline of treatments for rare diseases, personalized cancer vaccines, and infectious diseases. The success of mRNA COVID-19 vaccines has positioned RNA therapies as a key solution for future public healthcare and personalized cancer vaccines, attracting significant R&D investments. Universities, non-profits, life science companies, and other organizations continue to support advancements in RNA therapies for rare diseases, genetic disorders, and cancer.

However, safety and efficacy concerns remain, with the U.S. Department of Health and Human Services reducing and canceling investments in mRNA vaccine development, creating challenges for market participants. Companies are addressing these challenges through therapeutic diversification, partnerships and joint ventures, decentralized patient recruitment, and other strategies.

Therapeutic Areas Insights

The rare diseases segment led the market with the largest revenue share of more than 21.0% in 2025. According to Gene, Cell, & RNA Therapy Landscape Report, Q2 2025 Quarterly Data Report, published through a partnership between the American Society of Gene & Cell Therapy (ASGCT) and Citeline (part of Norstella), the 1,297 RNA therapies were in the pipeline, out of which 419 were for rare diseases. This signifies the dominance of this segment in the RNA therapy clinical trials market.

The anticancer segment is anticipated to grow at the fastest CAGR during the forecast period. The initial study on cancer vaccines is largely responsible for the success of the mRNA-based COVID-19 vaccines. The Pfizer/BioNTech and Moderna COVID-19 vaccines' development was sped up by utilizing the expertise of each company in the field of cancer vaccines. Personalized vaccines are developed based on the molecular structures of tumors from patients to detect genetic alterations that could give rise to neoantigens. To determine whether neoantigens will attach to T-cell receptors and elicit an immunological response, algorithms are used.

Modality Insights

The messenger RNA segment led the market with the largest revenue share of over 35.0% in 2025. The COVID-19 pandemic significantly accelerated the development and use of mRNA-based vaccinations, including the COVID-19 vaccines from Pfizer-BioNTech and Moderna. Due to the efficacy of these mRNA vaccines, mRNA technology has gained attention and shown promise in the fight against infectious diseases. Moreover, there are several potential uses for mRNA treatments in a variety of illness states. They can be used to encode specific proteins that produce therapeutic antibodies, activate an immune response, or restore protein function.

The RNA interference segment is anticipated to grow at the fastest CAGR during the forecast period. RNAi has shown potential therapeutic uses for a variety of disorders. It can be used to specifically target genes linked to rare genetic abnormalities or common diseases like cancer. RNAi can also be used to inhibit viral replication by targeting viral mRNA. As a result, RNAi treatments are attracting significant attention and funding for a range of disease indications.

Phase Insights

The phase II segment led the market with the largest revenue share of over 41.0% in 2025. Rising investment in R&D and an increasing number of industry- and non-industry-sponsored phase II clinical trials are major contributors to the segment's growth. Phase 2 studies enable the determination of the ideal dose and dosing regimen for RNA therapies.

The phase I clinical trials segment is expected to grow at the fastest CAGR during the forecast period. Regulatory bodies such as the U.S. FDA require data from phase 1 clinical trials to aid the advancement of RNA therapies into later-stage trials. Phase 1 trials provide critical safety data for regulatory submissions, such as Investigational New Drug (IND) applications, which are required to move on to the next stages of clinical research.

Regional Insights

North America dominated the global RNA therapy clinical trials market with the largest revenue share of more than 36.0% in 2025. This is attributed to the early adoption of RNA therapies, a robust research infrastructure, a regulatory environment, and a strong biotechnology and pharmaceutical industry. North America has been at the forefront of the development and early adoption of RNA therapies. Several key players in the field of RNA therapeutics are based in North America, and they have spearheaded clinical trials and advanced the translation of RNA-based therapies into the clinic. In addition, a significant number of RNA therapeutics have received FDA approval, and many are currently undergoing various stages of clinical studies to demonstrate their efficacy across a range of disorders.

To learn more about this report, Download Free Sample Report

Asia Pacific RNA Therapy Clinical Trials Market Trends

The RNA therapy clinical trials market in the Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period. Research and development efforts in the area of RNA therapies have rapidly increased throughout the Asia Pacific region. Academic institutions, research organizations, and biotech companies are actively engaged in RNA-based research in countries including China, Japan, South Korea, and Singapore, resulting in a growing pipeline of potential RNA therapeutics and increasing the number of clinical studies in the field.

Key RNA Therapy Clinical Trials Company Insights

The global RNA therapy clinical trials industry features a range of players at the global, regional, and local levels, making it a competitive market. The world’s leading companies are using partnerships, collaborations, acquisitions, mergers, and agreements as strategies to withstand the intense competition and increase their market share.

Key RNA Therapy Clinical Trials Companies

The following key companies have been profiled for this study on the global RNA therapy clinical trials market:

• IQVIA Inc.

• ICON Plc

• Labcorp.

• Charles River Laboratories.

• Parexel International (MA) Corporation.

• Syneos Health

• Medpace, Inc.

• Thermo Fisher Scientific Inc.

• Novotech

• Veristat, LLC.

Recent Developments

• In March 2026, BioNTech SE announced its plan to establish an independent company to advance next-generation mRNA innovations, with BioNTech’s contributions related to rights and mRNA technologies.

• In February 2026, a clinical-stage company, Ethris GmbH, announced that the European Health and Digital Executive Agency (HaDEA) had awarded it with USD 13.6 billion, as initial funds, for the NOFLU vaccine.

• In December 2025, BioNTech announced the acquisition of CureVac, strengthening the R&D, manufacturing capabilities, and commercialization candidates related to mRNA-based cancer immunotherapy.

Global RNA Therapy Clinical Trials Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities across each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the global RNA therapy clinical trials market report based on modality, clinical trials phase, therapeutic areas, and region:

• Modality Outlook (Revenue, USD Billion, 2021 - 2033)

  • RNA interference

  • Antisense therapy

  • Messenger RNA

  • Oligonucleotide, non-antisense, non-RNAi

• Clinical Trials Phase Outlook (Revenue, USD Billion, 2021 - 2033)

  • Phase I

  • Phase II

  • Phase III

  • Phase IV

• Therapeutic Areas Outlook (Revenue, USD Billion, 2021 - 2033)

  • Rare Diseases

  • Anti-infective

  • Anticancer

  • Neurological

  • Alimentary/Metabolic

  • Musculoskeletal

  • Cardiovascular Respiratory

  • Sensory

  • Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait